Assessing Analytical and Functional Similarity of Proposed Amgen Biosimilar ABP 980 to Trastuzumab.
Katariina M HuttererAlla PolozovaScott KuhnsHelen J McBrideXingxiang CaoJennifer LiuPublished in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2019)
Based on the comprehensive analytical similarity assessment, ABP 980 is analytically highly similar to the reference product, trastuzumab.